Leishmaniasis primary prevention

Leishmaniasis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Leishmaniasis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Leishmaniasis primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Leishmaniasis primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Leishmaniasis primary prevention
CDC on Leishmaniasis primary prevention
Leishmaniasis primary prevention in the news
Blogs on Leishmaniasis primary prevention
Directions to Hospitals Treating Leishmaniasis
Risk calculators and risk factors for Leishmaniasis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Pharmacotherapy

Acute Pharmacotherapies

Physicians may consult CDC to obtain information on how to treat leishmaniasis. The drug sodium stibogluconate is available under an Investigational New Drug protocol from the CDC Drug Service.

References

Template:WikiDoc Sources